Treatment of HIV-1 infection: Emtricitabin/Tenofovirdisoproxil Amarox is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1). Emtricitabin/Tenofovirdisoproxil Amarox is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents (see sections 4.2, 4.4 and 5.1). Pre-exposure prophylaxis (PrEP): Emtricitabin/Tenofovirdisoproxil Amarox is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).
Teva Pharmaceutical Industries Ltd. announced a proposal to acquire all of the outstanding shares of Mylan N.V. in a transaction...
Teva Pharmaceutical Industries announced that it has withdrawn its cash and stock proposal to acquire all of the outstanding ordinary...
Mylan N.V. announced that it has officially commenced its formal offer to acquire all outstanding ordinary shares of Perrigo Company...
Mylan N.V. announced that Mylan has made a proposal to acquire Perrigo Company plc in a cash-and-stock transaction that would...
Mylan N.V. announced that the FDA has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL...
Mylan N.V. and Biocon Ltd. announced that the FDA has accepted Mylan's Biologics License Application (BLA) for MYL-1401H, a proposed...
Mylan Inc. announced that it has, through its Indian subsidiary Mylan Laboratories Limited, signed a definitive agreement to acquire certain...
The Board of Directors of Meda AB hereby confirms that it has been contacted by Mylan, Inc.regarding an indicative proposal...
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. in relation...